Adalvo has received DCP approval for Azelastine/Fluticasone nasal spray, strengthening its respiratory portfolio and meeting key market needs.
This approval aligns with Adalvo’s clearly defined IP pathway, leveraging a complex, difficult-to-develop formulation designed for effective delivery, and enhancing patient accessibility.
Based on the reference brand Dymista®, Azelastine/Fluticasone targets seasonal and perennial allergic rhinitis. In 2023, Dymista® recorded global sales of approximately $278 million with a 3Y CAGR of 2%, according to IQVIA.
With a synchronised multi-country European launch targeted for Q1 2025, Adalvo is prepared to make a strong and coordinated market entry.
At Adalvo, there are no half-measures – we are always on target. When your mission is to outpace and outperform your competition, you need a winning team driving your vision forward.
Partner up now!